Ask AI

Decera Clinical Education's Independent Conference Highlights From the 2026 ASCO Annual Meeting

Review Capsule Summaries and a certified expert-authored ClinicalThought commentary highlighting key studies from the 2026 ASCO annual meeting.

For coverage of lymphoma and leukemia at ASCO and EHA 2026, click here.

Share

Program Content

Events

  • Live Event
    Decoding Breast Cancer Discoveries—Decera Clinical Education’s Independent Conference Highlights From the 2026 ASCO Annual Meeting
    Congratulations: You achieved a completion on 04/09/2022

    You can enroll in the following live event(s) on this topic.

Activities

RASolute 302
RASolute 302: Phase III Trial of Daraxonrasib vs Chemotherapy in Previously Treated Metastatic Pancreatic Adenocarcinoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2026

FIGHT-302
FIGHT-302: Phase III Trial of Pemigatinib as First-line Treatment for Unresectable Advanced or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 11, 2026

EMERALD-3
EMERALD-3: Phase III Trial of Tremelimumab + Durvalumab ± Lenvatinib Combined With TACE in Unresectable Embolization-Eligible HCC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 11, 2026

HERIZON GEA 01 PDL1 Subgroup Analysis
HERIZON-GEA-01: PD-L1 Subgroup Analysis From Phase III Trial of Zanidatamab + Chemotherapy ± Tislelizumab for First-line HER2+ Locally Advanced or Metastatic GEA
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 16, 2026

HORIZON-CRC01
HORIZON-CRC01: Phase III Trial of Trastuzumab Rezetecan vs SoC in Chemorefractory, HER2+ Advanced CRC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 16, 2026

Activities

IMforte Subtype and QTWiST Analyses
IMforte Phase III Trial: Transcriptomic and Q-TWiST Analyses of Lurbinectedin + Atezolizumab Maintenance Therapy in Extensive-Stage SCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 22, 2026

DeLLphi-304 Intracranial Efficacy
DeLLphi-304 Phase III Trial: Post Hoc Analysis of Intracranial Efficacy of Tarlatamab vs Chemotherapy as Second-line Treatment for SCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 24, 2026

HARMONi 6 OS
HARMONi-6 Phase III Trial: OS Outcomes With 1L Ivonescimab + Chemotherapy vs Tislelizumab + Chemotherapy for Advanced Squamous NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 24, 2026

LIBRETTO-432
LIBRETTO-432: Phase III Trial of Adjuvant Selpercatinib in Stage IB-IIIA RET Fusion–Positive NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 15, 2026

WU KONG28
WU-KONG28: Phase III Trial of First-line Sunvozertinib vs Platinum-Based Chemotherapy in Advanced NSCLC With EGFR Exon 20 Insertion Mutations
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 24, 2026

Activities

PIKALO 1
PIKALO-1: Phase I/II Study of Tersolisib + Endocrine Therapy ± CDK4/6 Inhibitors in PIK3CA-Mutant HR+/HER2- Advanced Breast Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 24, 2026

ASCENT 04 PFS2
ASCENT-04/KEYNOTE-D19: PFS2 With 1L Sacituzumab Govitecan + Pembrolizumab vs Chemotherapy + Pembrolizumab in PD-L1–Positive Advanced TNBC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 26, 2026

ASCENT 03 PFS2
ASCENT-03: PFS2 and Subsequent Therapies With 1L Sacituzumab Govitecan vs Chemotherapy in Metastatic TNBC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 26, 2026

Elacestrant Plus Capivasertib
ELEVATE Phase Ib/II Umbrella Study: Elacestrant Plus Capivasertib in Patients With Previously Treated ER+/HER2- Advanced Breast Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 26, 2026

SERENA 6 Update
SERENA-6 Update: Switch to Camizestrant With Continued CDK4/6 Inhibitor for Emergent ESR1 Mutations in ER+/HER2- Advanced Breast Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 30, 2026

TROPION Breast02 PFS2
TROPION-Breast02: PFS2 and Additional Efficacy Outcomes With 1L Dato-DXd vs Chemotherapy in Advanced TNBC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 30, 2026

NATALEE
NATALEE: Prognostic and Predictive Outcomes by Baseline Gene Expression in Patients Treated With Ribociclib + NSAI for HR+/HER2- Early Breast Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 07, 2026

OPTIMA
OPTIMA: Phase III Noninferiority Trial of Gene Expression–Directed Chemotherapy in Patients With High-Risk ER+/HER2- Early Breast Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 07, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

Supporters

Gastrointestinal Cancers
This activity is supported by an educational grant from Incyte Corporation.

Lung Cancer
This activity is supported by educational grants from Lilly and PharmaMar.

Breast Cancer
This activity is supported by educational grants from Lilly and Stemline Therapeutics, Inc. 

Incyte Corporation

Lilly

PharmaMar

Stemline Therapeutics, Inc.